HPS Pharmacies wish to advise that Fresenius Kabi have provided an update on the availability of Fresofol® (propofol).
During the COVID-19 pandemic, demand for critical medicines has increased significantly. In response, Fresenius Kabi have increased manufacturing to maximum capacity for medicines such as propofol. In order to maximise the efficiency of production and ensure continued supply of propofol, Fresenius Kabi have decided to focus on the manufacture of Fresofol® 20mL ampoules and Fresofol® MCT/LCT 100mL vials. This is a temporary change that eliminates the downtime associated with changing the vial size on the manufacturing line.
Impact to hospital clients:
- Supply of Fresofol® 20mL ampoules will continue as normal
- Fresofol® MCT/LCT 50mL vials will not be available until further notice
- Consider new imprest par levels for 100mL Fresofol® MCT/LCT, and potentially 20mL
- LCT only variants (Fresfol®) will not be available in the 50mL and 100mL presentations
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Fresenius Kabi on 1300 732 001.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates